Grand HiMedic Club Yokohama Bay Course Adopts AI Cognitive Self-Check App 'ONSEI Pro'
NQ Score
82/100
N1 Content Completeness
88
Key facts
- Grand HiMedic Club Yokohama Bay Course Adopts AI Cognitive Self-Check App 'ONSEI Pro'
- HiMedic, a 100% subsidiary of Resort Trust, will introduce ONSEI Pro — an AI voice-based cognitive function self-check app by Japan Tect Systems (DeNA subsidiary) — at its Yokohama Bay Course from June 5, 2026.
- Source: PR TIMES
- Date: Fri Jun 05 2026 00:00:02 GMT+0900 (Japan Standard Time)
Direct answer
HiMedic, a 100% subsidiary of Resort Trust, will introduce ONSEI Pro — an AI voice-based cognitive function self-check app by Japan Tect Systems (DeNA subsidiary) — at its Yokohama Bay Course from June 5, 2026.
- Citation
- Grand HiMedic Club Yokohama Bay Course Adopts AI Cognitive Self-Check App 'ONSEI Pro' (Fri Jun 05 2026 00:00:02 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Fri Jun 05 2026 00:00:02 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
HiMedic, a 100% subsidiary of Resort Trust, will introduce ONSEI Pro — an AI voice-based cognitive function self-check app by Japan Tect Systems (DeNA subsidiary) — at its Yokohama Bay Course from June 5, 2026.
AI Analysis
Frequently Asked Questions
- Q: What is ONSEI Pro?
- A: ONSEI Pro is an AI-powered cognitive function self-check app that analyzes and visualizes cognitive health by voice responses to tablet questions.
- Q: When and where was ONSEI Pro introduced?
- A: ONSEI Pro was introduced on June 5, 2026 at the Himedic Yokohama Bay Course operated through BASEGATE Yokohama Kannai Clinic.
- Q: Who developed ONSEI Pro?
- A: ONSEI Pro was developed by Nihon Tect Systems Co., Ltd., a subsidiary of DeNA Co., Ltd., based in Shibuya, Tokyo.
- Q: How does ONSEI Pro evaluate cognitive function?
- A: It provides a 5-level assessment from normal to MCI and dementia-equivalent, individually evaluating temporal orientation, memory, and attention.
- Q: What is the academic basis for ONSEI Pro?
- A: It was developed through research supported by AMED and joint research with Tokyo Jikeikai Medical University and Showa Medical University.